logo
#

Latest news with #Verve

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Malaysian Reserve

time4 days ago

  • Business
  • Malaysian Reserve

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)

Richard Ashcroft hilariously pokes fun at viral Oasis fan caught using Shazam to identify Bitter Sweet Symphony
Richard Ashcroft hilariously pokes fun at viral Oasis fan caught using Shazam to identify Bitter Sweet Symphony

Daily Mail​

time13-07-2025

  • Entertainment
  • Daily Mail​

Richard Ashcroft hilariously pokes fun at viral Oasis fan caught using Shazam to identify Bitter Sweet Symphony

Richard Ashcroft had the crowd at Heaton Park howling with laughter on Friday, after he referenced the now-viral clip of an Oasis fan struggling to to identify one of his greatest hits. The Verve frontman, 53, has been opening for Liam and Noel Gallagher on their eagerly-awaited reunion tour and winning rave reviews every night. However, at the band's opening gig at the Principality Stadium in Cardiff last month, one fan was caught unawares when the Verve began their iconic hit, Bitter Sweet Symphony, while the rest of 75,000-strong crowd sang along. In a clip shared to TikTok, the concertgoer could be seen opening up the Shazam app to try and identify the beloved 1997 track, which the Rolling Stone once named as one of the 500 Greatest Songs of All Time. The video was captioned: 'Imagine not knowing the greatest song of all time', and quickly went viral online, with many Verve fans furious by the perceived slight and declaring the fan in question didn't deserve their ticket. They raged: 'Seriously! I couldn't get a ticket because of these people'; 'This is the people who got our tickets'. 'If you don't know bittersweet symphony we can't be friends'; 'And there's real fans from the 90's that couldn't get tickets'. However, at the band's opening gig at the Principality Stadium in Cardiff last month, one fan was caught unawares when the Verve began their iconic hit, Bitter Sweet Symphony, while the rest of 75,000-strong crowd sang along 'nah there's no way i lost tickets to someone shazaming one of the most popular songs of the britpop era'; 'this is who i lost my tickets too'. But Richard evidently saw the funny side and took the opportunity to poke fun at the clip while opening for Oasis on Friday in their home city of Manchester. As he began the famous tune, he shouted out: 'Get your Shazams out!' sending a ripple of laughter through the crowd. While footage of the moment soon spread on social media, with one person tweeting: 'richard ashcroft encouraging people to shazam bitter sweet symphony might be the best thing i've seen today'. It comes after the crowd were blown away by Oasis' reunion as they delivered an electrifying set, packed with energy and nostalgia. Taking to social media to share their reactions, many lauded it as 'greatest rock n roll show of all time' as they praised the 'momentous' occasion. Comments included: 'LIAM SOUNDS SO F****G GOOD!!! OASIS ARE BACK. THIS IS BETTER THAN JESUS' RETURN!!!'; 'I died and ascended to a new plane'; While footage of the moment soon spread on social media, with one person tweeting: 'richard ashcroft encouraging people to shazam bitter sweet symphony might be the best thing i've seen today' 'The birth of my daughter 4 months ago was the best day of my life. tonight became the second best night of my life. To witness oasis with my dad and my brothers means the world to me what a night #Oasis #oasiscardiff'; 'Goosebumps. That was epic!!! #oasiscardiff #OASISLIVE2025'; 'Timeless. Absolutely f*****g incredible. You HAVE to go see them. Oasis are BACK '; 'If you think you've seen everything,I can confidently say that you haven't, unless you were inside the tonight for round 2 of @oasis @liamgallagher Rock n Roll is incredible! #Oasis #oasiscardiff #OASISLIVE2025'; 'What a performance that was tonight #Oasis #oasiscardiff #OASISLIVE2025'; 'Greatest rock n roll show of all time #Oasis #OasisLive25'; 'Oasis didn't just reform - they redeemed themselves. It wasn't just nostalgia. It was rebirth. #oasislive25'; 'Everybody who didn't get Oasis tickets and convinced themselves it wouldn't even be that good are now absolutely fuming… and I don't blame them. Mega. Just, mega. #oasislive25'; 'Anyone with tickets for #oasislive25 you are in for an absolute treat. I've never seen them so on form and it was banger after banger. Roll on Saturday at Heaton Park.' The video was captioned: 'Imagine not knowing the greatest song of all time', and quickly went viral online, with many Verve fans furious by the perceived slight and declaring the fan in question didn't deserve their ticket Kicking off the show, Liam and Noel walked out with their arms around each other in a sweet display of unity, before they proudly gazed on at the crowds, who erupted into rounds of deafening applause. As the masses gathered on Friday, Liam said: 'Manchester vibes in the area,' before he kicked off the show with Hello, which served as the opening track for their 1995 classic 'What's The Story (Morning Glory). They then went into Acquiesce - a song from their first 1995 album, which was followed by the iconic Morning Glory - the titular song of the second studio album. Liam shouted out: 'Yes beautiful people! It's been too long.' He then ordered the crowd to 'turn around and bounce' ahead of Cigarettes and Alcohol. After performing Some Might Say, Bring It On Down and Fade Away, Liam went off for a rest, while Noel performed his acoustic version of Talk Tonight. Then Noel appeared emotional as he performed Half The World Away and even stopped singing for a few bars at one point. Liam later said: 'Are you having a good time?' before addressing the ticket chaos: 'Was it worth the £40,000 you paid for the ticket.' Tickets were meant to start at £74.25 for seated tickets at their Wembley shows, with the most expensive ticket being a £506.25 pre-show party. The brothers put on a united front at their first show Throughout their various sets, poignant pictures of the family's home in Manchester flashed up on the screen along with baby pictures of both brothers. Old black and white pictures of their mum Peggy and dad Tommy were also flashed in the screen from time to time as Stand By Me played. The brothers ended the show with Rock n Roll, but fans cheers for an encore, with the pair strolling back out, with two of their fan favourite hits still to come. The crowds went wild as they belted out Wonderwall and the brothers became very emotional as they began to close down the show. 'Thanks for putting up with us over the years. We're hard work. We get it,' Liam gushed. They then rounded off their first gig in 16 years with legendary track Champagne Supernova.

Oasis setlist in full and stage times after Gallagher brothers' UK tour continu
Oasis setlist in full and stage times after Gallagher brothers' UK tour continu

Metro

time12-07-2025

  • Entertainment
  • Metro

Oasis setlist in full and stage times after Gallagher brothers' UK tour continu

To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video It's official – Oasis are back, and their first gigs in 16 years have been met with acclaim from fans, without any drama from the once-feuding brothers. Noel Gallagher, 58, and younger brother Liam Gallagher, 52, hadn't performed together since their 2009 split, meaning the world was, quite literally, sent into a frenzy last August when they confirmed the guns had 'fallen silent'. After a lengthy wait, the siblings kicked off their string of sold-out reunion shows at Principality Stadium in Cardiff, Wales, with Noel Gallagher reduced to 'tears' by the iconic moment. The brothers took to social media with a teaser of the stage, complete with an epic drone light show, ahead of that historic gig. With an international tour following their sold-out UK run, we're certain Oasis Live '25 has got plenty to give. So, what songs are on the setlist and what time do they hit the stage? The brothers aptly open their first show in 16 years with Hello – the first song on their second album, (What's the Story) Morning Glory? After that, it's fan-favourite tune Acquiesce and then Morning Glory, with the first half also including tunes Cigarettes & Alcohol, Supersonic, Roll With It, and Half the World Away. Hello Acquiesce Morning Glory Some Might Say Bring it on down Cigarettes & Alcohol Fade Away Supersonic Roll With It Talk Tonight (Noel sings) Half the World Away (Noel sings) Little by Little (Noel sings) D'You Know What I Mean Stand By Me Cast No Shadow Slide Away Whatever Live Forever Rock and Roll Star The Masterplan (Noel sings) Don't Look Back in Anger (Noel sings) Wonderwall Champagne Supernova Oasis are expected to sing 23 songs in total at each show based on the first setlist from July 4's show. Although who knows with these two. The latter part of the concert includes Rock and Roll Star, The Masterplan, Don't Look Back in Anger, and, of course, Wonderwall. Ending on a high, the brothers will close with Champagne Supernova, also the closing track on the band's second studio album, having saved their most popular tunes til the end. Oasis started their Cardiff show around 8:15pm. Before their set, Richard Ashcroft of the Verve took to the stage at 7pm to warm up the crowd with bangers, including Bittersweet Symphony. Well, bangers for most people – one woman was spotted Shazaming the iconic tune in the middle of the crowd. Sticking to the rules and behaving (for now), the concert was wrapped up minutes before the 10:30pm curfew of the stadium. Speaking just before the first show, a source hinted that Noel and Liam are still keeping some distance despite being on the road together. 'It's all gearing up now,' they began. 'Technical rehearsals for the band started on Monday, and then Noel and Liam joined them a couple of days later. 'But Liam barely even stayed for the first eight songs before leaving the rehearsals early, and Noel continued on his own.' Nevertheless, fans are absolutely beside themselves with excitement, as the responses to their X teaser video make clear. The official Oasis account previously shared further details about the structure of the night for the first tour show. Doors will open at 5pm before support acts Cast and Richard Ashcroft perform at 6pm and 7pm, respectively. Oasis will take to the stage at 8:15pm with a 10:30pm curfew, promising over two hours of music. The group will play 19 shows in the UK and Ireland this year before heading across Europe, with tickets sold to 900,000 fans. However, to say it's been smooth sailing getting here would be false. At the end of May, it was claimed that Noel and Liam still hadn't rehearsed together, with Liam also avoiding studio time with fellow performers Paul 'Bonehead' Arthurs, Gem Archer, Andy Bell, and Mikey Rowe. Instead, Liam, who is set to become a grandfather for the first time in a matter of months, has been chilling at his £4million mansion in the South of France with his girlfriend, Debbie Gwyther. Oh, and he's also been tweeting… Just this week, the singer offended a large number of South Korean Oasis fans by tweeting the phrase 'chingchong'. 'Chingchong' (believed to have originated in the 19th century) is understood as an offensive or derogatory phrase that's used to mock or denigrate East Asian languages. While usually intended to insult people who speak Chinese languages, it has also been applied towards languages and speakers from Japan and South Korea. Liam deleted the post shortly after and responded nonchalantly with 'Whatever' when one user warned he might get cancelled. It's believed Oasis will generate a whopping £400million in ticket sales and add-ons, just from their initial dates. As for their take-home pay, Noel and Liam are thought to be getting £50million each. More Trending But for those gutted to have missed out on tickets, have no fear, because after a disastrous first sale, the group announced last week that more tickets could become available. 'Oasis promoters may be able to release a very limited number of additional tickets for sale once final sight lines are checked and the production is fine tuned,' a statement read. 'These final production releases will happen over the coming days. If you are an Oasismynet member, keep an eye on your inbox for an email from your regular Oasismynet or Ticketmaster correspondence address. 'Please double check the email is from the correct account before following links or sharing any purchase information.' Got a story? If you've got a celebrity story, video or pictures get in touch with the entertainment team by emailing us celebtips@ calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you. MORE: Liam and Noel Gallagher's kids put on united front in 'pic of the century' MORE: I wasn't a Billie Eilish fan until her London gig completely changed my mind MORE: Readers discuss royal value, road rules, seagulls and Spitting Image

Don't sit on this deal! The best office chair we've tested is 20% off now for the final day of Prime Day
Don't sit on this deal! The best office chair we've tested is 20% off now for the final day of Prime Day

Tom's Guide

time11-07-2025

  • Business
  • Tom's Guide

Don't sit on this deal! The best office chair we've tested is 20% off now for the final day of Prime Day

Welcome, one and all, to the final day of this year's Amazon Prime Day sales! There's no time to waste as once these deals are gone, they are gone, and who knows when we'll see them next? I have a couple questions for you: do you sometimes work from home? Me too. And do you sit in a chair for 8+ hours a day? Me too! You need to look after your back and posture when you're sitting at a desk for hours and hours, so I've found a great deal on an office chair for you. Right now the Branch Verve is just just $519 at Amazon. That's a 20% discount on the chair that we've dubbed as the 'Best Office Chair Overall'! Save $130 on one of the best office chairs we've tested. It's available in five colors but we love the orange the most. The chair is designed to help keep you in an upright position while working comfortably for long hours at a time. Its 3D knit backrest helps keep you cool while its nylon casters prevent your hardwood floors from getting scratched. Like I said, the Branch Verve sits at the top of our best office chairs buying guide, and in our Branch Verve review, we awarded it 4.5 stars and the coveted Editor's Choice award. Its unique design combines style with comfort. It's highly ergonomic as it features adjustable lumbar support. The padded armrests also sink in slightly during use, making them very comfortable to rest your forearms on. We also love the unique 3D knit on the backrest which not only sets the Verve apart from its competition, but it's also breathable to help keep you cool. I don't know about you but I love that because I hate having a sweaty back when I'm working. The chair features six adjustment points to tailor it to your specific body type too, and it can accommodate up to. 275 pounds. If you're on the hunt for an office chair that has all other beats, I wouldn't sit on this deal (pun very much intended). You can grab the Branch Verve for just $519 at Amazon right now and save $130...

Verve Therapeutics, Inc. (VERV): A Bull Case Theory
Verve Therapeutics, Inc. (VERV): A Bull Case Theory

Yahoo

time10-07-2025

  • Business
  • Yahoo

Verve Therapeutics, Inc. (VERV): A Bull Case Theory

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research's Substack by Stock Region. In this article, we will summarize the bulls' thesis on VERV. Verve Therapeutics, Inc.'s share was trading at $11.26 as of June 26th. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. Verve Therapeutics' stock surged an astounding 75% following Eli Lilly's $1.3 billion acquisition announcement, signaling a pivotal moment for the biotech space. At the heart of this excitement is VERVE-102, Verve's lead drug candidate targeting cardiovascular disease. The therapy, which aims to eliminate chronic disease management through gene editing, could mark a paradigm shift in how heart disease is treated. The FDA's Fast Track designation for VERVE-102 further underscores the drug's breakthrough potential and validates Verve's scientific approach. Eli Lilly's substantial bid is a clear vote of confidence, suggesting the pharma giant sees transformational value in Verve's pipeline. The acquisition not only provides financial validation but also shines a light on the evolving landscape of biotech, where high-impact innovation meets large-scale pharmaceutical backing. From a technical perspective, bullish momentum remains strong above $11.27, with caution advised if the stock dips below $10.95. Beyond the numbers, this deal exemplifies how cutting-edge therapies are attracting serious capital and reshaping the future of medicine. The excitement surrounding Verve's breakthrough technology and Eli Lilly's aggressive investment underscores the growing belief in gene editing as a frontier in healthcare. For investors, this move by Lilly isn't just about Verve—it reflects a broader confidence in biotech's ability to redefine chronic disease care. With VERVE-102 leading the charge and now bolstered by big pharma support, Verve appears well-positioned at the intersection of innovation and real-world impact, making this a landmark moment for the company and the sector at large. Previously we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by Two Natural Cap in June 2025, which highlighted the company's role in a groundbreaking base-editing therapy for a rare liver disorder. The company's stock price has appreciated approximately by 12.4% since our coverage. The thesis still stands as CRSP advances gene-editing leadership. Stock Region shares a similar outlook but emphasizes Verve's cardiovascular focus. VERV isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VERV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store